AliveCor Mobile ECG now available in Canada

AliveCor, Inc., the leader in FDA-cleared ECG technology for smartphones, announced today that the AliveCor Mobile ECG is now available for patients and physicians in Canada. With the AliveCor Mobile ECG and the AliveECG app users can instantly detect the presence of atrial fibrillation (AF or AFib), a leading cause of stroke, in an electrocardiogram (ECG or EKG) and manage their heart health with an FDA-cleared and Health Canada Licensed electrocardiogram ECG monitor, anywhere and at anytime.

AF is the most common cardiac arrhythmia and increases the risk of stroke up to five times. Due to Canada's aging population, AF is a growing problem. One-in-four Canadians over 40 years of age will suffer from AF in their lifetimei. Stroke is a leading cause of death and disability in Canada and is a devastating condition, causing stress for both patients and their families and costing the healthcare system more than $2.5 billion annuallyii. Additionally, the death rate of AF-related strokes is twice as high as from strokes unrelated to AFiii. The good news is that 3 out of 4 strokes can be prevented if detected and treated.

"We are excited to be able to provide credible healthcare solutions that stop the unnecessary loss of life driven by undiagnosed and under-managed heart arrhythmias, which are on the rise in Canada. The availability of mobile devices like the AliveCor Mobile ECG will be of great benefit to those affected, their families, and the healthcare system," said Euan Thomson, chief executive officer of AliveCor. "Being able to understand what is going on inside heart disease through data analytics has the potential to change the way we think about and participate in our healthcare. AliveCor is excited about being on the forefront of consumerizing medicine and helping more people globally."

AliveCor has seen tremendous growth throughout the past four years including expanded regulatory clearances, the launch of three algorithms, and recently surpassing 2.5 million ECGs recorded into the AliveCor database that are being used to develop powerful insights about heart health. Additionally, the company more than doubled the number of regular users and recordings in the last year and continues to expand globally entering nine new countries in 2015.

"We have seen the global impact of the AliveCor Mobile ECG for both patients, physicians and caregivers and are thrilled that it is now available in Canada, a vital community for us and our fight against heart arrhythmias," said Trudie Lobban MBE, Founder & CEO of AF Association, Arrhythmia Alliance and STARS (Syncope Trust). "This is an effective and efficient tool to help monitor and manage arrhythmias and we look forward to their continued expansion."

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AliveCor, Inc.. (2019, June 18). AliveCor Mobile ECG now available in Canada. News-Medical. Retrieved on April 26, 2024 from https://www.news-medical.net/news/20150619/AliveCor-Mobile-ECG-now-available-in-Canada.aspx.

  • MLA

    AliveCor, Inc.. "AliveCor Mobile ECG now available in Canada". News-Medical. 26 April 2024. <https://www.news-medical.net/news/20150619/AliveCor-Mobile-ECG-now-available-in-Canada.aspx>.

  • Chicago

    AliveCor, Inc.. "AliveCor Mobile ECG now available in Canada". News-Medical. https://www.news-medical.net/news/20150619/AliveCor-Mobile-ECG-now-available-in-Canada.aspx. (accessed April 26, 2024).

  • Harvard

    AliveCor, Inc.. 2019. AliveCor Mobile ECG now available in Canada. News-Medical, viewed 26 April 2024, https://www.news-medical.net/news/20150619/AliveCor-Mobile-ECG-now-available-in-Canada.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AliveCor receives CE Mark clearance for algorithm to detect atrial fibrillation